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Abstract
There is much interest in characterizing the variation in a human individual, because this may elucidate what contributes
significantly to a person’s phenotype, thereby enabling personalized genomics. We focus here on the variants in a person’s
‘exome,’ which is the set of exons in a genome, because the exome is believed to harbor much of the functional variation.
We provide an analysis of the ,12,500 variants that affect the protein coding portion of an individual’s genome. We
identified ,10,400 nonsynonymous single nucleotide polymorphisms (nsSNPs) in this individual, of which ,15–20% are
rare in the human population. We predict ,1,500 nsSNPs affect protein function and these tend be heterozygous, rare, or
novel. Of the ,700 coding indels, approximately half tend to have lengths that are a multiple of three, which causes
insertions/deletions of amino acids in the corresponding protein, rather than introducing frameshifts. Coding indels also
occur frequently at the termini of genes, so even if an indel causes a frameshift, an alternative start or stop site in the gene
can still be used to make a functional protein. In summary, we reduced the set of ,12,500 nonsilent coding variants by ,8-
fold to a set of variants that are most likely to have major effects on their proteins’ functions. This is our first glimpse of an
individual’s exome and a snapshot of the current state of personalized genomics. The majority of coding variants in this
individual are common and appear to be functionally neutral. Our results also indicate that some variants can be used to
improve the current NCBI human reference genome. As more genomes are sequenced, many rare variants and non-SNP
variants will be discovered. We present an approach to analyze the coding variation in humans by proposing multiple
bioinformatic methods to hone in on possible functional variation.
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Introduction
Genetic variation in the protein-coding portion of genes is of
significant interest in the study of human health. The focus on
coding exons, or the ‘exome’, is due to the common belief that the
exome harbors the most functional variation [1]. This is based on
the observation that mutations that cause Mendelian diseases
occur primarily in genes [1,2]. Mutations that cause amino acid
substitutions, including changes to nonsense codons, in their
respective genes are the most frequent type of disease mutation
(,60%) [1]. In addition, small indels in genes account for almost a
quarter of the mutations in Mendelian disease [1,2]. Meanwhile,
less than 1% of Mendelian disease mutations have been found in
regulatory regions. For complex diseases, such as Alzheimer’s,
obesity, and heart disease, it is unknown how much variation in
genes will contribute to disease, compared to variation in
regulatory regions [3,4].
There have been many efforts to re-sequence genes to identify
and characterize gene variation in humans [5–11]. One of the
proposals of the 1000 Genomes Project, an international
collaboration that aims to sequence one thousand genomes,
focuses specifically on re-sequencing coding exons [12]. Addition-
ally, many groups are developing technology for high-throughput
resequencing of exons [13–15].
Because there has been much progress in sequencing individual
human genomes [16–20], our understanding of functional variation
is an important step towards an era of personalized medicine, where
a doctor could inform patients’ of their disease susceptibilities based
on their genome sequences. If the exome harbors much of the
functional variation responsible for a person’s phenotype, then
identification and characterization of the individual’s variation in the
exome could enable individualized genomics.
In this study, we focus our analysis on the exome of an individual
human by providing a detailed characterization of the variants in
protein-coding regions. We present the analysis of the coding
variantsinan exomefrom adiploidhuman genomeassembly,which
was termed HuRef [16]. This paper analyzes the different types of
nonsilent coding variants. There are ,12,500 coding variants that
change protein sequence in the HuRef genome. We show that most
of the variation in this individual is common and appears to be
functionally neutral. Furthermore, we are able to reduce the
,12,500 coding variants down to ,1,600 variants that potentially
affectproteinfunctionand maybeinvolvedinphenotypiceffects.To
the best of our knowledge, this is the first analysis of the exome of an
individual human, and may serve as a benchmark for future studies
on the variation in human exomes.
There are several aspects to this study. The first is to describe a
snapshot of what personalized genomics means today. If a person
was to have his genome sequenced today, we show what insights
about the individual could be gleaned from the protein coding
component alone. Another aspect is that we can use the HuRef
variants to improve the current NCBI reference genome, which
PLoS Genetics | www.plosgenetics.org 1 August 2008 | Volume 4 | Issue 8 | e1000160will simplify future analysis of additional genomes. The final aspect
is how one could characterize the variation obtained from
sequencing many individual human genomes, and the approaches
that could be developed to mitigate these studies. This is our first
glimpse of an individual’s human genome and as additional
genomes are sequenced, many rare variants and non-SNP variants
will be discovered. From this first exome, we can see what
challenges one might encounter and propose approaches to face
these challenges. Thus we present one approach for the analysis of
coding variation in a human by detecting different trends for each
variant type and demonstrating what phenotypes can be
interpreted with our current knowledge.
Results
Nonsynonymous SNPs
This individual has 10,389 nsSNPs, of which 5,604 are
heterozygous and 4,785 are homozygous (Table 1), where homozy-
gousvariantsarelociwheretheallelesdifferfromtheNCBIreference
genome, but are the same within the HuRef assembly. It has been
previously estimated that the number of heterozygous nsSNPs in an
individual ranges from 24,000 to 40,000 [6]; our observed value of
5,604 is much less than this. This estimate was based on the
nonsynonymous substitution rate based on a small number of genes,
a n de x t r a p o l a t i n gt h i sv a l u ea c r o s sa l lg e n e s .T h eo v e r e s t i m a t ei s
partly due to the assumption of the human genome having 45,000–
100,000 genes, but even if we assume the human genome has
20,000–30,000 genes, the estimate remains 1.5–26higher than what
we report. Possible explanations for the discrepancy is that the
substitution rate in genes is extremely variable due to differences in
local rates of mutation and recombination [6]. Thus we believe our
number tobe more accuratebecause it examinesallgenesrather than
extrapolating from a small gene set.
The nsSNPs account for a little more than half of the coding
SNPs in the diploid genome (Table 1). The 1:1 ratio of
nonsynonymous SNPs to synonymous SNPs agrees with previously
published reports [6,8]. Approximately 7% of the nsSNPs were
not found in dbSNP and are thus novel. We expect novel SNPs to
be rare [21–23] and hence observed on a single chromosome in an
individual. This was affirmed with the observation that 72% of the
novel nsSNPs are heterozygous.
Most nsSNPs in an Individual Are Common
We wanted to find nsSNPs in this individual that may be
undergoing negative selection. We use allele frequency in the
human population as an indicator that a variant might be under
negative selection. According to the theory of natural selection,
functionally neutral mutations can reach high minor allele
frequencies, whereas deleterious mutations will be selected against
and remain rare in a population. Rare variants do not necessarily
have to be deleterious; they can be recent mutational events.
Variants that are neutral, slightly deleterious, or under positive
selection can become common in a population.
To see what proportion of nsSNPs may be undergoing negative
selection, we retrieved the allele frequencies of these nsSNPs from
the HapMap Project [24,25] (Figure 1). The majority of HuRef
Figure 1. The allele frequencies of heterozygous and homozy-
gous nsSNPs in HuRef. For heterozygous SNPs, the minor allele
frequency is plotted. For homozygous nsSNPs, the frequency for the
observed allele in HuRef is plotted.
doi:10.1371/journal.pgen.1000160.g001
Author Summary
Characterizing the functional variation in an individual is
an important step towards the era of personalized
medicine. Protein-coding exons are thought to be
especially enriched in functional variation. In 2007, we
published the genome sequence of J. Craig Venter. Here
we analyze the genetic variation of J. Craig Venter’s
exome, focusing on variation in the coding portion of
genes, which is thought to contribute significantly to a
person’s physical make-up. We survey ,12,500 nonsilent
coding variants and, by applying multiple bioinformatic
approaches, we reduce the number of potential pheno-
typic variants by ,8-fold. Our analysis provides a snapshot
of the current state of personalized genomics. We find that
,1% of variants are linked to any known phenotypes; this
demonstrates the dearth of scientific knowledge for
phenotype-genotype associations. However, ,80% of an
individual’s nonsynonymous variants are commonly found
in the human population and, because phenotypic
associations to common variants will be elucidated via
genome-wide association studies over the next few years,
the capability to interpret personalized genomes will
expand and evolve. As sequencing of individual genomes
becomes more prevalent, the bioinformatic approaches
we present in this study can be used as a paradigm to
pursue the study of protein-coding variants for the
genomes of many individuals.











*All heterozygous novel nonsynonymous SNPs were manually inspected (see
Methods).
doi:10.1371/journal.pgen.1000160.t001
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79% of the homozygous nsSNPs, the NCBI human genome has
the minor allele (MAF,0.5). Therefore, the homozygous nsSNPs
in HuRef tend to represent the major alleles in the human
population and it is likely that the majority of these homozygous
nsSNPs are neutral because they have reached such high
frequencies. Also, 19% of the homozygous alleles in HuRef have
an allele frequency of 1, which suggests that NCBI contains a rare
or erroneous allele at these positions. The majority of HuRef
heterozygous SNPs are also common with only 9% of the nsSNPs
with known allele frequencies being rare (MAF,0.05).
Since we do not have allele frequencies for all the HuRef
nsSNPs, we must estimate the proportion of rare nsSNPs
(MAF,0.05) in this individual. A previous simulation has
estimated that ,28% of heterozygous SNPs in an individual are
rare, but that study made assumptions about human population
size and its growth [26]. For 67% of the nsSNPs with known
HapMap allele frequencies, we know the exact number of rare
nsSNPs (56 homozygous and 326 heterozygous). For the
remaining 33% of nsSNPs with unknown allele frequencies, we
can estimate the proportion of rare nsSNPs based on the
sequencing of a subset of heterozygous novel nsSNPs and the
fraction of rare homozygous SNPs with known allele frequencies
(see Methods). Using this approach, we estimate ,1,600–2,000
rare nsSNPs in this individual’s genome, the lower bound takes
into account the ,25% false positive rate for novel SNPs (see
Methods). We conclude that ,15–20% of the nsSNPs in an
individual are rare, and ,95% of the rare nsSNPs are
heterozygous (see Methods). The number of rare variants found
in this individual may guide our expectations when we sequence
additional genomes in the future.
nsSNPs Likely to Affect Protein Function Tend to be
Heterozygous, Rare, or Novel
We wanted to identify the nsSNPs that may affect protein
function and possibly be involved in human health and
undergoing negative selection. Algorithms exist that predict
whether an amino acid substitution affects protein function based
on sequence conservation and/or structure [27–34]. When
applied to human nsSNPs from re-sequencing projects, 0–30%
of nsSNPs are predicted to affect function [9,31–33,35]. This
range is based on datasets containing a relatively small number of
nsSNPs (,50–600) in a small number of genes (,100–200).
What distinguishes our analysis from previous reports [9,31–
33,35] is that we examine a single individual, rather than a
population of individuals – thus we are establishing a benchmark for
individualized genomics, as opposed to population genetics.
Furthermore, we study all genes, unlike the previous studies that
focused on certain classes of genes that were selected for their
possible relevance in human health. For our study, we use the
algorithm,SIFT(Sorting Intolerant FromTolerant)to determine ifa
nsSNP may affect protein function [33]. SIFT takes into account
whether the amino acid change resulting from a nsSNP lies in the
conserved region of the protein and the type of physiochemical
change, and outputs a prediction to whether a nsSNP may affect
protein function. We note that SIFT and other amino acid
substitution prediction algorithms [27–34] only predict whether a
nsSNP affects protein function. These algorithms do not predict
whether a variant alters the processing or stability of transcripts.
Approximately 75% of the HuRef nsSNPs had SIFT predic-
tions (see Methods), and 14% were predicted to impact protein
function (Figure 2). This suggests that the majority of nsSNPs in
this individual are functionally neutral. It also indicates that an
individual has ,1,500 (14% of 10,389) nsSNPs that affect protein
function with deleterious effects, and we are able to confirm a
previous estimate [34]. This previous estimate was obtained by
taking the average nonsynonymous nucleotide substitution rate
(based on a small number of genes) and extrapolating it for all
genes. Meanwhile our estimate is based on the actual number of
observed nsSNPs in an individual.
The ,1,500 nsSNPs predicted to affect protein function are
deleterious in the evolutionary sense with each nsSNP having a
selection coefficient s<10
23, on average [34]. A small selection
coefficient suggests that the deleterious nsSNP either has negligible
effects on health, has effects late in life after reproduction has
occurred, or causes a disadvantage in certain environments. We
term the nsSNPs predicted to affect protein function as predicted-
protein-affecting nsSNPs. The other ,9,000 nsSNPs are effec-
tively neutral mutations with 0,s,10
24, assuming an effective
population size of 10,000 [36]. Thus, the effects of nsSNPs span a
Figure 2. The percentage of nsSNPs predicted to affect protein function, by category. A higher fraction of heterozygous, novel, and rare
nsSNPs are predicted to affect function compared to homozygous and common nsSNPs. Rare nsSNPs have allele frequencies ,0.05; common nsSNPs
have allele frequencies .=0.05.
doi:10.1371/journal.pgen.1000160.g002
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predicted-protein-affecting nsSNPs tend to be more detrimental.
Heterozygous nsSNPs are two times more likely to be predicted
as protein-affecting compared to the homozygous nsSNPs
(p,0.001; Figure 2). We reason that predicted-protein-affecting
nsSNPs are expected to be selected against and therefore, less
likely to both reach high allele frequencies and be observed in
homozygote form. Rare nsSNPs are also two times more likely to
be predicted as protein-affecting compared to common nsSNPs
(p,0.001; Figure 2) and this trend has been reported previously
[9,10,35]. This suggests that a higher proportion of the rare
nsSNPs are deleterious, and are more likely undergoing negative
selection. Also, a higher percentage of novel nsSNPs and nsSNPs
with unknown allele frequencies are predicted to be protein
affecting compared to all the nsSNPs (Figure 2), but this difference
only holds for the heterozygous SNPs and not the homozygous
nsSNPs (Figure S1; Text S1).
Therefore, novel, rare, and heterozygous nsSNPs are more
likely to affect protein function and cause phenotypic effects. Yet
rare and novel nsSNPs are difficult to characterize because they
are underpowered in whole-genome association studies [4]. Thus,
one of the major challenges in the future of genomics is how to
correlate rare and novel nsSNPs with phenotypes.
SNPs that Cause Premature Termination Codons
There are 105 HuRef SNPs that result in premature
termination codons, or stop codons, in 103 genes, hereafter
referred to as PTC-SNPs. This corresponds to 0.5% of coding
SNPs. These SNPs are expected to result in the loss of their
respective proteins and hence be under strong negative selection.
Yet when we retrieved allele frequencies for PTC-SNPs, all of the
36 PTC-SNPs with known allele frequencies were common, which
shows that not all PTC-SNPs are under strong purifying selection.
We investigate possible reasons for why some PTC-SNPs are not
under strong negative selection and are able to reach high allele
frequencies in the human population. Thirty percent (31/105) of the
PTC-SNPs occur in segmental duplications in the human genome
compared to 9.8% for synonymous SNPs. We assume gene
redundancy would rescue these mutations, although loss of one
copy of a gene can still have quantitative effects [37]. It is also
possible that these PTC-SNPs have been mistakenly mapped due to
the difficulty of assembling highly duplicated regions.
We remove the PTC-SNPs in segmentally duplicated regions
from consideration and 74 PTC-SNPs in 73 genes remain. A
substantial fraction (42%) of the remaining genes with PTC-SNPs
are hypothetical. Hypothetical genes containing common PTC-
SNPs may not be important to the human population, and using
these variants may improve annotation of the human genome. If
the PTC-SNPs in hypothetical genes are removed from consid-
eration, 43 PTC-SNPs in 42 genes remain, and we sought to
characterize these further.
Because we saw that three times as many PTC-SNPs occur in
segmental duplications than expected, we postulated that multiple
copies of a gene may permit the existence of a PTC-SNP. We
examined the size of the gene family for the remaining 42 genes, and
found that the median gene family size is 6, which is higher than the
median gene family size for all genes, which is 2 (p,0.001). Thus,
PTC-SNPs tend to occur in genes that have other homologues
present in the genome, which may rescue the full or partial loss of a
related gene [38]. There are only 9 PTC-SNPs in 8 genes that are
non-hypothetical and unique members of their gene family.
In general, PTC-SNPs tend to occur in hypothetical proteins,
segmentally duplicated regions, and gene families with multiple
members. In the future, we may be able to use these trends to
prioritize which PTC-SNPs are most likely to have functional
consequences. All the PTC SNPs in HuRef can be found in Table
S1, and none are in genes known to be involved in disease.
Coding Indels
Indels are the second most abundant type of genetic variation,
following single nucleotide substitutions and account for almost a
quarter of the genetic variation implicated in disease [2]. Coding
indels can significantly impact their corresponding genes if they
introduce frameshifts that lead to unfinished protein products.
The HuRef genome contains a total of 739 coding indels, which
consists of 281 heterozygous indels and 458 homozygous indels.
To the best of our knowledge, this is the largest set of human
coding indel variants identified to date [39].
We find an enrichment of indels that have sizes that are
multiples of 3 in the HuRef coding indel set (Figure 3). We will
Figure 3. The size distribution of coding indels. Coding indels are predominantly the size of 3n, where n is an integer. 3n coding indels do not
cause frameshifts, whereas non-3n coding indels do.
doi:10.1371/journal.pgen.1000160.g003
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indels with lengths not divisible by 3 as non-3n indels, where n is an
integer. In coding regions, a non-3n indel would cause a frameshift
that usually leads to a truncated protein product whereas a 3n indel
would cause deletion or insertion of amino acid(s). By comparing the
diversityratesbetweencodingindelsandindelsgenome-wide(Figure
S2), we find that 94% of non-3n coding indels have been eliminated
by natural selection. In contrast, only 46% of 3n coding indels have
been eliminated. This signifies that 3n coding indels are not as
strongly selected against as non-3n indels.
Many of the indels are due to polymorphism in tandem repeat
sequence. Only 6% of coding regions are classified as tandem
repeats, yet 52% (381/739) of all coding indels occur in tandem
repeats. The majority (73%) of the tandem repeats in coding
regions have a periodicity of 3 and account for 66% (252/384) of
the 3n bp coding indels. This suggests that local regions in a
protein coding sequence can be prone to mutation that will either
remove or insert amino acids into the protein product.
In contrast to SNPs, many indels are not validated and their
allele frequencies are unknown due to difficulty in their
ascertainment using either sequencing or genotyping technologies
[39,40]. To validate these indels, we verified if the indel was
confirmed in the chimpanzee genome sequence [41]. We
determined that 24% (181/739) of the coding indels correspond
to the chimpanzee sequence. These indels are likely to be common
in the human population if the indels occurred before the
divergence of chimpanzee and human, although an alternative
possibility is that some of these mutations are recurring events.
This signifies that at least 24% of the HuRef coding indels are real.
We sought explanations of how an individual human genome
could have 739 indels affecting 607 genes, and yet the individual
appears to lack severe phenotypic effects. Small coding indels
(,=30 bp) account for 84% (621/739) of the indels. In the
following section, we analyze the 621 small coding indels
(,=30 bp). Large indels are discussed in a later section.
Coding Indels Are Not Randomly Located in Their
Proteins
Many of the small coding indels were located at the N- and C-
termini of their respective proteins. We calculated the relative
position of the indel in the protein by dividing the indel’s position
by the total protein length. With this metric, one would expect that
the indel’s position would be uniformly distributed across the
protein. Instead, indels tend to occur at the N- and C-termini of
their proteins (Figure 4). If a coding indel occurs at the C-terminus
of the protein, it may not affect the function of the protein because
most of the protein product has been translated successfully. If a
coding indel occurs at the N-terminus of the protein, this may be
rescued by a downstream start codon in the coding region (see
Figure S3 for an example). This suggests that indels at the N- and
C-termini of their proteins are functionally neutral and a future
study using these indels to propose alternate start and stop sites
could improve human gene annotation.
Furthermore, a high proportion of homozygous coding indels
were located near an exon boundary. A large proportion of the
small homozygous coding indels were within 10 bp of the exon
boundary: 27% (101/344) compared to 12% (34/277) for small
heterozygous coding indels. Close inspection of the homozygous
indels near exon boundaries showed that these indels were near
small introns and the HuRef allele corrects the NCBI reference
genome to provide a better gene model. Figure 5 shows an
example where a 1-bp homozygous coding insertion borders a
2 bp intron, so rather than causing a frameshift, the small intron is
replaced by an amino acid. Incorporating the homozygous indel
from HuRef likely produces the correct protein sequence.
Therefore, it is very likely that the HuRef assembly has the
correct sequence, and could potentially be used to correct gene
structures that were based on the NCBI human genome. Many of
these small homozygous indels within 10 bp of an exon boundary
were also found in chimp (61% (62/101)), further evidence that
these indels are the ancestral alleles and likely to be accurate.
We re-sequenced seven homozygous non-3n indels that were
either near exon boundaries (4), and/or confirmed by chimp (4),
and/or at the N-terminus of a protein (1) (see Methods). These
non-3n indels would supposedly cause frameshifts, yet all seven
indels were found to be common (MAF.0.05) and four were
determined to have an allele frequency of 1 (Table S2). This
indicates that NCBI has a rare or erroneous allele at these
positions and suggests that homozygous indels located at certain
locations may correct the NCBI genome sequence.
We assume that indels near protein termini and near exon
boundaries are functionally neutral. Removing these indels from
the indel set reduces the entire set by 45%, with 342 indels
remaining. Of the remaining indels, the fraction of indels that have
length 3n increases from 49% (303/621) to 60% (205/342). This
suggests that while the termini of a protein may be able to tolerate
the presence of non-3n bp indels, elsewhere in a protein there is a
greater preference for 3n indels.
We categorize the remaining indels by their 3n and non-3n
lengths. Whereas 35% (71/205) of 3n indels are found in
hypothetical proteins, 56% (77/137) of non-3n indels are found in
hypothetical proteins (p,0.001). This suggests that non-3n indels
occur in genes that can tolerate deleterious mutations, which may be
pseudogenes or genes under weak selective constraints and we may
be able to use these variants to identify genes that are likely not
important for human health. We also noticed that the 3n coding
indels that are not in tandem repeats tend to avoid regions of the
protein that are highly conserved (Figure S4).
In summary, many of the indels are located at exon boundaries
or protein termini and these are likely to be functionally neutral.
The remaining coding indels typically have sizes of 3n, and those
that do not tend to occur in hypothetical proteins. To the best of
our knowledge, these trends have not been previously reported,
Figure 4. Location of coding indels. On the x-axis is the relative
protein location of the coding indel, which is the first amino acid
position of the indel divided by the protein length. A relative protein
location near zero indicates that the indel is located near the N-
terminus of the protein and a relative protein location near one
indicates that the indel is located near the C-terminus of the protein.
Indels occur frequently at the N- and C-termini of proteins.
doi:10.1371/journal.pgen.1000160.g004
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functionally neutral. In the future, we can use the HuRef indels to
improve gene annotation and our observations to develop a
method that distinguishes between functional and neutral indels.
Genes with Missing or Partial Exons
We sought to understand genes missing large regions of coding
sequence, leading to a gene and/or exon deletion that would
render the gene non-functional. Therefore, we focused on
deletions of coding sequence in this analysis. We will discuss
newly observed genes and insertions of coding sequence in existing
genes in a future manuscript.
We identified 1,454 exons in 1,046 genes where at least half of
the coding exon’s sequence was missing from the HuRef assembly.
Further investigation showed that genes with ‘‘missing’’ exons are
most likely due to low coverage or assembly issues with repetitive
regions rather than the human individual truly missing part of a
gene (see Methods and Text S1; Figure S5). This was confirmed by
resequencing a subset of the missing exons in the HuRef sample
and validating that in fact, most of the ‘‘missing exons’’ are present
in the HuRef sample (see Methods and Text S1).
Variants in Disease Genes and their Associated
Phenotypes
We examined the HuRef variants in genes known to be involved
in disease (based on the OMIM database [42]) to make
correlations between the HuRef variation and possible pheno-
types. There are a total of 682 nsSNPs in 443 disease genes (Table
S3). The allele frequency distribution and fraction of predicted-
protein affecting SNPs are similar to non-disease genes (Figure S6).
We examined the nsSNPs from dbSNP [43] that were found in
the disease database OMIM [42] (see Text S1). Using this
approach, seven HuRef nsSNPs were found to be associated with
disease (Table 2). The HuRef individual is heterozygous for all
seven SNPs and most of these disease-associated SNPs are
common in the population. It may be considered surprising that
these nsSNPs are common since they were found in the OMIM
disease database. This is due to the fact that we looked for overlap
with nsSNPs that are in both OMIM and dbSNP, and dbSNP
tends to be biased for common SNPs [21].
From these seven variants, one could simplistically infer that the
HuRef individual has an increased risk for eating disorder (BDNF),
1.5-fold reduced risk to multiple myeloma (LIG4), an increased risk
to prostate cancer which can be rescued by taking vitamin E
supplements (SOD2), and allergic tendencies (SPINK5) (Table 2).
Some of the SNPs have known interactions with environmental
factors (SOD2 and BDNF in Table 2). However, the published risks
for these variants are from population-based studies, and may not
apply to this specific individual because it does not take into account
other interacting genetic loci and his environment [44–47].
Therefore, Table 2 does not show exact risks for this individual
and predicting the phenotype or lack of phenotype of this individual
is premature. These variants, like many of the risk variants being
uncovered by genome-wide association studies, have low risks and
wemaynothaveaclearunderstandingoftheirclinicalutilityuntilall
the relevant factors (both genetic and environmental) for a particular
disease have been elucidated [44–47].
These seven well-studied examples demonstrate the complexity
of trying to interpret variants and their impact, but there are still
many variants in this individual that are uncharacterized. For the
682 nsSNPs in 443 disease genes, 27 are rare (MAF,0.05), 18 are
novel, and 81 are predicted to affect function (Table S3).
Interpretation of these variants is difficult because of the absence
of literature for many of the observed variants. One challenge is
that these variants, even if they affect protein function, could be
phenotypically neutral in certain contexts (see SOD2 and BDNF
in Table 2 and [48]). Also, even if there is evidence that a nsSNP is
under negative selection (e.g. predicted to affect function and/or
rare), it is not straightforward to interpret a possible phenotype
because mutations at different locations in the same gene can have
different effects [49]. The difficulty of inferring phenotypic
consequences from a variant is depicted in the following example.
rs562556, which is homozygous in HuRef and has an unknown
minor allele frequency, introduces the amino acid substitution
V474I in PCSK9, and this amino acid substitution is predicted to
affect protein function. Because defects in PCSK9 cause familial
hypercholesterolemia (OMIM:607786), one could speculate that
this SNP could affect the donor’s cholesterol levels. However,
extensive functional studies of this variant and others are necessary
before any conclusions can be made. Because only 1% (7/682) of
the nsSNPs in disease genes in this individual human have been
well-characterized, this indicates that we are only at the beginning
of relating genotypes to phenotypes, even for the well-character-
ized disease genes.
Figure 5. An example of a homozygous indel located near an exon boundary. The HuRef assembly has a homozygous insertion of A at
chr11: 44881936. This insertion resides inside a coding exon of the gene TP53I11, but is near a 2 bp intron. With this new base inserted, a single
amino acid is introduced into the protein sequence, which is the more likely scenario instead of a 2 bp intron.
doi:10.1371/journal.pgen.1000160.g005
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of the 28 indels have lengths that are not multiples of 3n, and
would cause frameshifts. Two of these indels appear to be
annotation issues and are likely to be functionally neutral (see Text
S1). The third indel is in ACOX2. This protein is involved in lipid
metabolism, and patients with Zellweger syndrome lack this
protein [50]. Because the indel is heterozygous in the HuRef
individual and one functional copy is present, the individual may
not be adversely affected by this mutation.
For the remaining 25 indels with length 3n in 23 disease genes,
84% were in tandem repeats. Some of these genes are known to
cause disease due to polyglutamine and polyalanine repeat
expansions (AR, ATXN2, ATXN3, HD, TBP). For these genes,
we confirmed that the number of repeats in the HuRef genome
falls within the range of what is observed for unaffected
individuals. In addition, this individual is heterozygous for a 24-
bp duplication in the CHIT1 gene, which activates a cryptic 39
splice site and causes chitinase deficiency [51]. Even though the
indel produces a nonfunctional protein, the indel is observed at an
allele frequency of 23% in the general population. One possibility
for its high incidence is that this indel may provide a selective
advantage against fungal pathogens [51].
Selective Constraints on the Human Genome
To examine selective constraints on different regions across the
genome, we estimated the diversity rate h (see Methods). We
calculate the diversity rates for regions throughout the entire
genome as well as calculating the diversity values for genic regions
(Table 3). Values of h tend to be negatively correlated with the
strength of selection, where low values of h tend to indicate strong
selective pressures, while high values do not. The order of h is:
coding in disease genes,coding,conserved noncoding intro-
nic,splice sites,39UTR<59UTR<conserved noncoding inter-
genic,promoter,introns,repeats. This indicates that coding





V74M Increased risk for eating disorder OR=1.6 [84]
Met/Met: Inferior episodic memory [85]
Met/Met: Later onset of Parkinson’s disease [86]
Met: In bipolar patients, less adaptive to change [87]
Predicted to affect protein function.
d
rs1800556 ACADS MAF=0.17
R171W ACADS with 171W has residual activity (45%). Because this is polymorphic in the control population, this is a predisposition
allele that can cause SCAD deficiency if additional factors are present [88].
Predicted to affect protein function.
c
rs1805389 LIG4 MAF=0.02; MAF=0.07 in [89]
A3V 1.5-fold reduction in risk of developing multiple myeloma for heterozygotes [89].
Predicted to be functionally neutral.
d
rs13073139 BTD MAF=0.17 [90]
A171T Biotinidase deficiency, asymptomatic in heterozygous form [91]. A171T is in linkage disequilibrium with D444H and D444H
results in 48% of normal enzyme activity. We confirmed that HuRef is heterozygous for D444H. It is unknown whether A171T
produces nonfunctional enzyme.
A171T is predicted to be functionally neutral.
D444H is predicted to affect protein function.
c
rs2303067 SPINK5 MAF=0.48. Associated with allergies, atopic dermatitis, asthma, and total serum IgE. Paternally derived alleles tended to be
less often associated with disease than maternal alleles [92]
E422K Predicted to be functionally neutral.
d
rs11556045 HEXB MAF=0.22. Observed in a patient with juvenile Sandhoff disease, but the patient had another mutation which activated a
cryptic splice site. This SNP is unlikely to be the causative variant. [93]
K121R Predicted to be functionally neutral.
rs4880 SOD2 MAF=0.44. Risk of prostate cancer depends on genotype, vitamin E uptake, and smoking status. For the heterozygote, there
is an increased risk of prostate cancer. Val/Val: OR=1. Val/Ala OR=1.17 Ala/Ala=1.28
A16V This risk is increased with smoking and low vitamin E uptake [94].
Within hereditary haemochromatosis patients, carriers of the Val allele have a higher prevalence of cardiomyopathy [95].
Mutant protein has 30–40% lower activity.
Predicted to be functionally neutral.
c
aAll of these SNPs were heterozygous in HuRef.
bOR=odds ratio. We note that these associations should be interpreted with caution because there are disagreements in the published literature [94,96–98]. Additional
genotype-phenotype relationships for this individual can also be found in Table 13 of [16].
cThree nsSNPs have been shown to cause reduced protein activity. Of these, two are predicted to affect function.
dThree nsSNPs associated with disease but for which enzymatic assays have not yet been carried out (to the best of our knowledge) and are presumed to be involved in
disease. It is possible that these nsSNPs are not the etiological variants but instead they could be in linkage disequilibrium with the etiological variants. One of these
three nsSNPs is predicted to affect protein function.
doi:10.1371/journal.pgen.1000160.t002
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regions and repeats are the least. Some diversity values and trends
have been reported in previous publications [6–8,52,53], and our
results are in agreement with these values. However, to our
knowledge this is the first study with such an extensive list of
regions. We also find indels are significantly under-represented in
coding regions; there is a 43:1 SNP:indel ratio for coding regions
compared to a 7:1 SNP:indel ratio genome-wide. It is reasonable
to observe stronger selection against indels in coding regions where
they can introduce frameshifts.
We further explored if the observed HuRef variation could
indicate whether certain genes were under stronger selective
constraints than others. We identified 538 genes containing
common nsSNPs located in conserved regions of the protein and
are predicted to affect protein function. We called this set of genes
the Commonly-Affected genes. In parallel, we identified 79 genes
containing rare nsSNPs predicted to affect protein function, and
we termed this set the Rarely-Affected genes.
We hypothesized that Commonly-Affected genes would be
under weaker selective constraints since predicted-protein-affect-
ing SNPs, common in the human population, were found in these
genes. Ka/Ks, is a metric used to quantify selection of a gene and is
calculated as the ratio of the nonsynonymous (amino-acid
affecting) substitution rate to the synonymous substitution rate. A
high Ka/Ks ratio indicates that a gene is undergoing weak
selection, although positive selection is also a possibility if Ka/Ks is
.1 across the entire gene or part of the gene [54]. We observe that
the Commonly-Affected genes tend to have higher Ka/Ks ratios
than the Rarely-Affected genes (p=0.09; Figure 6). This suggests
that Commonly-Affected genes may not be under strong selective
constraints. Presumably, mutations affecting gene function in the
Commonly-Affected genes will not have significant consequences
on human health, which is why these predicted-protein-affecting
nsSNPs can rise to high allele frequencies. In support of this
hypothesis, the Commonly-Affected genes are dominated by
olfactory receptors (78/538) which is consistent with the previous
observation that humans do not depend on olfaction to the same
extent as other species [55].
In the future, extending this type of analysis to nsSNPs from
HapMap or additional human genomes may allow identification
of additional Commonly-Affected genes. This could help improve
the scientific community’s knowledge of the human genome by
identifying which genes may not play an important role in human
health if mutated.
Comparing Individual Genomes
We also compared the genome properties of Dr. James Watson
[20] to those of Dr. Craig Venter. SNP diversity rates based on Dr.
Watson’s genome are slightly elevated compared to Dr. Craig
Venter’s (Table 3), but in general, follow a similar trend as stated
previously. The one exception is simple repeats, which have a 2-
fold higher SNP diversity rate in Dr. Watson compared to Dr.
Venter; this may be due to differences between sequencing
technologies.



















Total 6.2 0.9 6.5
Gene Regions
CDS 3.6 0.08 Filtered: 0.09 4.0
CDS of disease
genes
2.9 0.06 Filtered: 0.04 3.0
Constitutive exons 3.5 0.08 Filtered: 0.08 4.0
Alternative exons 4.6 0.1 Filtered: 0.06 4.8
59UTR 4.4 0.3 4.9
39UTR 4.7 0.7 5.1
Splice sites 4.0 0.6 4.6
Promoter ( 1 kb
upstream)
5.4 0.8 6.1
Introns 5.6 0.9 6.2
Conserved Elements
All 4.3 0.5 4.9





All 6.6 1.2 7.5
Alu 7.2 2.6 7.5
MIR 5.6 0.3 6.1
MER 6.3 0.5 7.0
LTR 7.2 0.4 8.0
L1 6.6 0.6 7.2




aThe diversity rates based on Dr. Venter’s and Dr. Watson’s genomes are
probably underestimated by ,25%, the percentage of heterozygotes missed
due to low read coverage [16,20].
bFor coding indels, we show the diversity values before and after filtering. Some
diversity values for indels are higher after filtering because homozygous indels
were re-classified as heterozygous indels.
cFor Dr. Watson’s genome, we assume that the entire genome was covered by
reads, which will also lead to an underestimate (see Methods). There is a large
difference between the diversity values for Dr. Watson’s and Dr. Venter’s
genome for simple repeats. This may be due to the methodological differences
between Sanger and 454 technologies.
doi:10.1371/journal.pgen.1000160.t003
Figure 6. The Ka/Ks ratios of Commonly-Affected genes and
Rarely-Affected Genes. Commonly-Affected genes have a higher Ka/
Ks ratio than Rarely-Affected genes, which suggests that Commonly-
Affected genes are under weaker selection.
doi:10.1371/journal.pgen.1000160.g006
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NCBI genome, 56% are shared with Dr. Watson. There are
606,719 and the 288,723 novel SNPs that map to the NCBI
human genome in Dr. Watson’s and Dr. Venter’s genomes,
respectively. One possible reason for the smaller number of novel
SNPs in Dr. Venter’s genome is because Dr. Venter’s genome is
partially represented in the Celera human genome assembly
[16,56], and variants have been mined from the Celera assembly
and subsequently deposited in dbSNP [57]. Of the novel SNPs,
only 32,528 SNPs are shared between the two individuals. This
demonstrates the value of sequencing additional human genomes
to discover novel variants.
We compare the number of nsSNPs and coding indels between
the two exomes (Table 4). Similar numbers of nonsynonymous
variants are detected in both individuals. However, 14% and 20%
of nsSNPs are predicted to affect function in Dr. Venter’s and Dr.
Watson’s exomes, respectively. One possible reason for this
difference could reside in the different prediction algorithms
employed [20,30,33]. Future analyses that use a standardized
approach may clarify this apparent difference. The number of
indels in Dr. Watson’s genome is less than half of the number of
indels we observe in HuRef (Table 4), most likely because 1 bp
indels were discarded [20]. As more individuals are sequenced,
scientists will be able to establish general trends and the average
values for metrics that characterize a human individual’s genome.
Discussion
Coding exons are believed to be rich in functional variation
because many coding mutations have been found to cause
phenotypic effects [58]. As a result, re-sequencing projects tend
to focus on coding regions [5–11], multiple technologies that
specifically target the exome are being developed [13–15,58], and
the 1000 Genomes Project may specifically target the exome [12].
This motivated us to focus on the variation in an individual’s
exome to see what insights could be gleaned. Protein-coding exons
are thought to amount to a little less than half of the functional
portion of the genome; noncoding highly conserved regions
constitute the other half [59–62]. We did not analyze noncoding
variants even though they can be involved in disease [3,63–66]
because exons are the best characterized regions that correlate to
phenotypes and it is difficult to characterize the impact of
noncoding variants at this time. As our understanding of non-genic
regions increases, so can we expand our interpretation since the
data for this individual’s entire genome is available.
Personalized Genomics Today
This is the first study of an individual’s exome and we establish
what one may expect to observe from the variation in the exome of
an individual. We show that the majority of coding variants in a
human are neutral or nearly neutral. This is not unexpected, since
we know that this genome creates an individual who has survived
past 60 years of age. We also find that within an individual, the
basic principles of genetics are followed. Additionally, we
examined the variation in genes known to be involved in disease,
and found no indication that the individual should have a severe
disease, which matches the phenotype currently known.
Despite having a human’s complete genome sequence, we are
only at the tip of the iceberg for understanding how an individual’s
genotype and phenotype are related. One significant challenge is
that the phenotypic effects of the majority of genes are unknown.
Currently, only 7% of genes are annotated with OMIM disease
associations so that it is difficult to predict the phenotypic effects of
variants for a large proportion of genes. If one is to rank genes by
importance and effect on phenotype, then based on the results of
this study, one might consider that genes containing PTC-SNPs,
frameshifting indels, and damaging nsSNPs that are common in
the human population to be under weak selection, and variants in
these genes may not be as relevant to human health. Several
groups have used gene ontology, literature, and other sources to
predict potential disease genes [67,68], we propose that one can
also use observed human variation to increase our understanding
of the human genome.
Even if a gene is known to be involved in disease, it is difficult to
understand if a variant in the gene will have a phenotypic effect.
We found that 99% of the nsSNPs in disease genes could not be
characterized by current literature. Different mutations in the
same gene can cause different phenotypic effects [49], thus making
it difficult to interpret possible phenotypes. Furthermore, some
variants have phenotypic effects only under certain environments
(see SOD2 and BDNF in Table 2 and [48]). Also, when looking at
complex phenotypes, multiple variants in coding and non-coding
regions are likely to be involved [63–66]. This genetic complexity,
as well as exposure to various environmental factors, will need to
be taken into account in assessing risk for various diseases.
How can geneticists start to grasp the significance of phenotype-
genotype correlations? This question is especially relevant to
companies offering personalized genomics to their consumers (e.g.
23andMe, Navigenics, deCODE Genetics). When looking
amongst the human population, there are many rare SNPs, but
when looking at a single human individual, the majority of the
SNPs are common [6,69,70], and in this study we estimate that
.80% of the nsSNPs in an individual are common. Therefore,
understanding which common variants are involved in common
disease will greatly benefit an individual, because common variants
account for a significant fraction of the variation in each human.
Recent genome-wide association studies have identified common
variants implicated in disease [71–73] and these studies will
continue to find common disease-associated variants in the near
Table 4. Characterization of Dr. Venter’s and Dr. Watson’s exomes. Numbers for Dr. Watson’s exome are taken from [20].
Dr. Venter’s Exome Dr. Watson’s Exome
Total Number of Nonsynonymous SNPs 10,389 10,569
Number of Novel Nonsynonymous SNPs 772 (7% of total nsSNPs) 1,573 (15% of total nsSNPs)
% nsSNPs predicted to affect protein function* 14% (7,781 predicted on) 20% (3,898 predicted on)
Number of Coding Indels 739 345**
*Different prediction algorithms were used [30,33], and this may account for the difference between the two exomes.
**Indels of size 2 bp and greater were considered; 1 bp indels were discarded. If we removed 1 bp indels from Dr. Venter’s exome in order to compare with Dr. Watson’s
exome, Dr. Venter would have 423 coding indels.
doi:10.1371/journal.pgen.1000160.t004
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proportion of an individual’s genome. However, one should be
cautious in the interpretation of these variants because variants
with low associated risks may not necessarily have good
predictability in the clinical setting [44,45].
In contrast, rare variants are harder to study because genome-
wide association studies are insufficiently powered to detect rare
variants [4]. We found that a higher fraction of rare nsSNPs were
predicted to affect protein function compared to common nsSNPs,
in agreement with previous studies [9,10,35]. This suggests that a
small proportion of a large number of common variants and a
larger proportion of a small number of rare variants will contribute
to the health of a human individual. Genome-wide association
studies tend not to have the power to detect rare etiological
variants [4] so that predicting whether a rare mutation in an
individual causes disease without any other phenotypic informa-
tion is extremely difficult. Therefore, one of the major future
challenges in personalized genomics is the interpretation of the
effects of rare variants found in an individual, especially if this
information will be relayed back to the individual and could
impact the person’s lifestyle.
In addition to interpretation and analysis, much effort was
expended in ensuring that a variant was authentic (see Methods).
There could be unintended negative consequences for telling a
person that they have a disease variant, when in actuality the
variant could be detected in error. Common reasons for our false
positive variant calls were technical sequencing error, low
sequence coverage, and low-complexity sequence. When inter-
preting an individual’s genome that can potentially impact a
person’s lifestyle, manual curation, editing, and verification by
other technologies seems prudent.
Improving the Currently Available Reference Human
Genome Sequence
The human genome sequence has had a significant impact on
research since its availability in 2001 [56,74], but our analysis
suggests that rare or erroneous alleles may have been incorporated
into the NCBI human genome sequence, and that this sequence
can be corrected and improved. Because one of the goals of the
1000 Genomes Project is to improve the human reference
sequence [75], our study points to where such improvements
can be made. We find that ,80% of the homozygous SNPs in
HuRef tend to be the major allele in the population (Figure 1), and
,20% of the homozygous HuRef nsSNPs had allele frequencies
equal to 1. Thus, at the majority of HuRef homozygous positions,
the NCBI human reference sequence has the minor allele. If the
scientific community sequenced many individuals, it could
determine the major allele at each position in the genome. If the
major allele was incorporated into the coding sequence, and this
was used in subsequent gene prediction models, then the
predominant form of the protein in the human population would
be represented instead of a rarer form. Also, by using the common
allele instead of the sometimes rarer NCBI allele, the number of
perceived variation would be reduced when comparing human
genomes. For example, if the NCBI human genome sequence
were to incorporate the major allele and HuRef was then
compared to this modified NCBI genome sequence, then we
estimate the new number of HuRef homozygous SNPs genome-
wide would be ,300,000 (0.2 * 1.45 million [16]) and the number
of total variants between HuRef and the modified NCBI would
reduce from 4.1 million [16] to 3 million. Similarly, if we remove
the homozygous nsSNPs that correspond to the common allele in
European population (AF.0.5), then the fraction of rare nsSNPs
increases by 6%. This demonstrates the importance of the human
genome reference sequence for the evaluation of variation in
individual human genomes.
The scientific community could also make use of coding indel
variation to correct and improve gene annotation. Indels near
exon boundaries appear to provide the correct gene models to give
the appropriate protein product (Figure 5, for example) [76]. Gene
annotation for translation starts and stops can be further refined
based on our observation that coding indels are found frequently
at the N- or C-termini of their proteins. Frameshifting-indels at the
N-termini of proteins could indicate that a translation start site
further downstream may be the true start codon, or at least an
alternative start codon can still yield a functional protein. Indels
such as these may be polymorphic and so accounting for these
indels could simplify future analyses on exomes as they could be
quickly regarded as functionally neutral and reduce the total
number of indels that need to be analyzed.
We also observed a trend where common predicted-protein-
affecting nsSNPs, PTC-SNPs and frameshift-inducing indels tend
to occur in hypothetical genes. This suggests that these genes are
not under strong selective pressures and mutations in these genes
may not be relevant in the human population. Future studies with
more human sequences identifying additional nonfunctional
mutations in genes would help us confirm whether these genes
are essential.
Sequencing of Many Human Genomes
Our exome analysis is currently limited to one individual.
However, there will be significant benefits from sequencing many
individuals whose phenotypes are known. One can envision
collecting the genetic variation from these genomes and grouping
individuals based on their respective phenotypes. Then for each
phenotype, one may discover the genes which are involved in
disease by looking collectively at the rare and common variants
[11,77,78]. The analysis can also be strengthened by analyzing
pathways instead of individual genes [78].
Furthermore, whole genome sequencing means we need not be
limited to the exome. Using whole genomes, one could look for
clustered mutations in conserved regulatory elements, especially
since many association studies have found disease-associated loci
in non-coding regions [63–66]. To assess the role of noncoding
variation, we examined HuRef variation in and around genes
involved in the melanoma pathway because the HuRef donor has
reported a case of melanoma (Figure S7). We found that the
majority of the variants occurred in conserved noncoding regions.
This suggests that it may be insufficient to sequence just the exome
and it is important to understand all types of variation, coding and
noncoding, as well as interactions with the environment when
studying phenotypes.
Conclusion
We have filtered the initial set of ,12,500 coding variants that
affect protein sequence to a substantially smaller set that are most
likely to have major effects on gene function (Figure 7). The trends
that we have detected suggest we can reduce the number of
putative functional coding variants by ,8-fold and will provide a
future guide for how one can analyze coding variants when
additional human genomes are sequenced in the future.
Additionally, the variants found here and in future studies may
be used to improve our understanding of the human genome by
correcting gene annotation and identifying genes not likely to be
relevant to human health. We anticipate that this study will help
guide the scientific community’s expectations and experimental
design in future genome sequencing projects.
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Variant Set
We used the filtered variant set as described in [16]. We define
homozygous variants as loci where the alleles differ from the NCBI
reference genome, but are the same within the HuRef assembly.
This variant set was used to generate the diversity values in Table 3.
For all other sections in this manuscript, quality inspection of
variants was performed. To assure the quality of novel coding
variants, we inspected manually the sequencing traces of novel
heterozygous nsSNPs, all heterozygous PTC-SNPs, and all coding
indels lessthan20 bpinlength. The sequencetraces for these coding
variantswereextractedand three peopleindependentlyreviewed the
traces, by examining the quality of the traces and determining
whether the variant was correctly called. If at least two people
confirmed the existence of the variant, the variant was deemed
acceptable, otherwise the variant was discarded. 35% (424/1196) of
the novel heterozygous nsSNPs, 12% (9/73) of the heterozygous
PTC-SNPs, and 33% (355/1088) of the coding indels were
discarded. This may suggest that a significant fraction of the variants
reported in [16] are dubious. However, this analysis is restricted to
coding variation which is known to be under strong selection
compared to the rest of the genome. Hence, there will be fewer real
variants in coding regions and a higher proportion of the novel
coding variants will be false positives. 20% (123/611) of the
homozygous indels were reclassified as heterozygous because there
was trace evidence for a second allele.
The importance of filtering is demonstrated with the following
observation. Manual inspection reduces the number of novel
nsSNPs by a third, but especially filters out a higher proportion of
predicted-protein-affecting nsSNPs. Prior to filtering, the number
of novel heterozygous predicted-protein-affecting nsSNPs is 195,
after filtering this is more than halved to 89 novel nsSNPs
predicted to affect protein function.
SNP Characterization
SNPs not found in dbSNP v. 126 [43] were designated as novel.
All allele frequencies were based on the CEU samples genotyped
from the HapMap Project [24,25], unless otherwise stated. Allele
frequencies for 72% (3429/4785) of the homozygous nsSNPs and
63% (3544/5604) of the heterozygous nsSNPs were obtained. For
heterozygous SNPs, we report the minor allele frequency (MAF).
For homozygous SNPs, we report the CEU allele frequency of the
allele observed in the HuRef genome. We define common SNPs as
SNPs with allele frequencies .=0.05 and rare SNPs with allele
frequencies ,0.05.
The amino acid changes resulting from coding variants were
determined by SNPClassifier, an internally developed software
tool. The HuRef variants, their alleles, and positions in genomic
coordinates, are provided as input into SNPClassifier. Annotation
is automatically retrieved from Ensembl and is used to assign
variants to defined gene categories. Variants in or near genes can
be subtyped as: promoter (1 kb upstream of the transcription start
site), intronic, 59 UTR, 39UTR, coding, or downstream of the
transcript (1 kb). Coding SNPs are designated either as synony-
mous or nonsynonymous and coding indels are designated as
either frameshift or amino acid insertions/deletions. The resulting
Figure 7. A summary of the nonsilent coding variants and their observed trends.
doi:10.1371/journal.pgen.1000160.g007
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also output.
SIFT predictions for nonsynonymous SNPs were obtained by
using SIFT 2.1.1 [33]. The protein sequences containing
nonsynonymous SNPs were searched against SwissProt-Trembl
54. Confidence in predictions is measured by the median sequence
information, we used a cutoff of 3.5 for confidence. Approximately
75% (7,781/ 10,389) of the nsSNPs had SIFT predictions, the
remaining 25% did not have a sufficient number of homologous
sequences that are needed for prediction.
Estimating Number of Rare NsSNPs
We estimate the number of rare nsSNPs with allele frequency
(AF) ,0.05 in an individual. For the 67% nsSNPs with known AFs
from the HapMap Project, there are 56 rare homozygous nsSNPs
and 326 rare heterozygous nsSNPs. For the 1,356 homozygous
nsSNPs with unknown AFs, the percentage predicted to affect
function is similar to that seen for homozygous SNPs with known
AFs (Figure S1). If the homozygous nsSNPs had a higher
proportion rare SNPs, then a higher fraction should be
predicted-protein-affecting but because they are similar, we
assume that the homozygous nsSNPs with unknown AFs have a
similar proportion of rare SNPs as the homozygous nsSNPs with
known AFs. Because 1.6% (56/3429) of the homozygous nsSNPs
with known AFs are rare, we estimate ,22 (1.6% * 1,356) of the
homozygous nsSNPs with unknown AF are rare, so in addition to
the 56 rare homozygous nsSNPs with known AF, there is a total of
,80 rare homozygous nsSNPs in this individual. For heterozygous
nsSNPs, there are 326 heterozygous rare nsSNPs with known
MAF, and 2,060 heterozygous nsSNPs with unknown MAF. From
sequencing, as much as a quarter of the heterozygous nsSNPs with
unknown MAF could be false positives, although this estimate is
likely to be an upper bound (see Sequencing for Variant
Validation in Methods). Therefore the range of novel heterozy-
gous nsSNPs falls within ,1,550–2,060. We also ascertained from
sequencing that ,75% of the heterozygous novel nsSNPs are rare.
Therefore, we estimate that ,1,200–1,550 of the heterozygous
nsSNPs with unknown MAFs are rare and in total, there are
,1,500–1,900 rare heterozygous nsSNPs. Thus, we estimate
,1,600–2,000 rare nsSNPs in this individual’s genome, and
,95% of the rare nsSNPs are in heterozygous state.
Indel Characterization
For an indel’s location, we calculated the relative position of the
indel in the protein by taking the first amino acid position affected
by the indel. We divided the position by the total length of the
protein, so that a relative protein position value close to 0 indicates
that the indel affects the N-terminus of the protein, and a relative
protein position value close to 1 indicates that the indel affects the
C-terminus of the protein. We designate that an indel affects the
N-terminus of a protein if the relative protein position is between 0
and 0.1; an indel affects the C-terminus of a protein if the relative
protein position is between 0.9 and 1.0. Thus, an indel is said to
affect the N-terminus or C-terminus of the protein if it lies within
the first 10% or last 10% of the open reading frame, respectively.
To examine whether an indel occurs in a conserved region of
the protein, the sequence alignment of the protein sequence with
homologues from other organisms were retrieved from Ensembl.
At every position in the protein alignment, sequence conservation
was calculated [79]. The conservation value at the indel’s position
is compared with all other positions, and the percentile rank is
calculated. If the number of sequences in the alignment was less
than 10, the data point was removed.
Genes Missing Exons
The HuRef assembly was mapped by an assembly-to-assembly
comparison to the NCBI build 36 human reference genome [16].
Regions in NCBI reference that were missing in the human
diploid assembly were identified. We intersected the missing
regions with coding exons greater than 50 bp in length and
ensured that at least 50% of the exon was missing from the HuRef
assembly in order to consider the exon. To double-check that the
missing sequence was not in unassembled sequence, we searched
the exonic sequence using MEGABLAST [80] against the HuRef
assembled sequence and the unassembled singletons. MEGA-
BLAST hits greater than 95% identify and with 50 bp minimum
length were kept. We decided exons were not truly missing if
.90% of its length were covered by these MEGABLAST hits.
The final set consisted of 1,454 exons in 1,046 genes.
We removed the genes located on sex chromosomes because the
sex chromosomes are known to have low coverage [16]. After
removing these genes, there were 719 genes with 880 missing or
partial exons. To investigate read depth for this set of exons, we re-
mapped all untrimmed reads from [16] to the set of exons using
‘snapper’ (http://kmer.wiki.sourceforge.net/), a seed-and-extend
mapper. All 20-mer seeds were extended, and any alignments over
94% identity were reported. As a control, we also remapped reads
to a set of exons that were randomly selected from all exons.
Whereas the control exons show a normal distribution with the
median number of reads centering at 7.6, the missing exons show a
bimodal distribution with either very few reads or many reads
(Figure S5b). This reflects that genes with ‘‘missing’’ exons are
most likely due to assembly issues with repetitive regions or low
coverage. 66% of the ‘‘missing’’ exons have an average read depth
of less than 2 reads, which emphasizes the importance of adequate
coverage in a human genome.
Sequencing for Variant Validation
We generated PCR primers to 15 regions in 12 genes with
‘missing exons’, 9 PTC-SNPs, 15 coding indels, and 26 novel
heterozygous nsSNPs (Table S2). These 65 PCR primers
consistently amplified their cognate genomic regions in 46
unrelated CEU individuals and the HuRef sample. The DNA
for the HuRef sample was extracted from whole blood (see
Methods in [16]). We sequenced the PCR products using Sanger
dideoxy sequencing (see [16] for sequencing protocol). The 46
unrelated CEU individuals were part of the HapMap CEU panel,
and their Coriell identifiers are provided in Table S2.
Of the 26 heterozygous novel nsSNPs, 6 failed to be confirmed
in the HuRef sample and instead matched the NCBI allele. There
was also 1 nsSNP that failed to be confirmed in the HuRef sample
but was observed in other samples and this was considered to be a
false negative. This suggests that the false positive error for
HuRef’s novel nsSNPs is ,25% (23%=6/26). This estimate is
likely to be an upper bound due to the following reason. The 26
nsSNPs occurred in non-hypothetical genes, and nsSNPs in
hypothetical genes may be under little or no selective pressures
compared to nsSNPs in non-hypothetical proteins and the former
can reach high allele frequencies. Hence, this false positive error
may be inflated. For the novel nsSNPs that we could confirm in
HuRef, the mean MAF of the novel SNPs was 0.09 and 74% (14/
19) of the SNPs were rare (MAF,0.05).
For the PCR products spanning missing exons, 14 regions from
11 genes were successfully amplified in the HuRef sample and this
confirmed that HuRef is not missing exons for these genes (Table
S2). In the 12th gene PRED58, a 66 bp coding deletion in HuRef
was observed but this was seen in all other DNA samples,
suggesting that NCBI has the rare or erroneous allele.
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All genome coordinates are with respect to NCBI build 36 and
all gene designations are with respect to Ensembl v. 41. A gene was
considered hypothetical if in its gene description, it had no
description or was described as an ‘‘open reading frame’’, an ‘‘orf’’
which signifies an open reading frame, a cDNA clone, putative,
probable, uncharacterized, ‘‘similar to’’ another protein, a
pseudogene, a fragment, hypothetical, a novel protein, novel
transcript, or if it was invalid as described in Clamp et al. [81].
Under this classification, there were 20,561 non-hypothetical
genes and 10,624 hypothetical genes consisting of 29,401,727 bp
and 6,176,706 bp respectively. Ka/Ks is the ratio of the
nonsynonymous substitution rate to the synonymous substitution
rate. Ka/Ks values based on human-mouse orthologous gene pairs
were retrieved from Ensembl Biomart. In Table 3, constitutive
exons are those coding exons that are expressed in 100% of the
transcripts for its given gene. If a coding exon was present in
,50% of the transcripts, it was designated as an alternative exon.
Splice sites include the 20 bp within exon boundaries (10 bp
intronic, 10 bp exonic for each exon boundary).
Segmental duplication regions were taken from the UCSC
genomicSuperDups file (.1 kb length, .90% identity). Tandem-
RepeatFinder [82] was used to designate tandem repeats using the
parameters match=2, mismatch=5, delta=5, PM=75, PI=20,
minscore=35.
Non-genic conserved regions were taken from phastConsEle-
ments17way that were .=50 bp in length. If any part of the
PHAST region intersected with coding, 59UTR, and/or 39UTR,
the PHAST conserved element was removed. Therefore, the
conserved regions in Table 3 were not overlapping or bordering
coding, 59UTR, or 39UTR regions.
Sequence Diversity





is the number of variants identified, L is the number of base pairs,
and n is the number of alleles. For indels, K is the number of indel
events. In the case of a single diploid genome, n=2, so a reduces
to 1. Then h=K/L which is simply the number of heterozygous
variants divided by the length sequenced. The 95% confidence
interval for h is [0, h+2h] or [0, 3h], as calculated in [16].
Diversity values were calculated for the various types of regions
listed in Table 3 and the counts for these values can be found in
Table S5. We also attempted to look at the diversity values for
gene ontology categories, but were unable to do so because of the
low numbers of coding variants per gene (data not shown).
Diversity values for Dr. James Watson’s genome were calculated
using the 1.86 million heterozygous SNPs reported in [20]. For the
denominator L, we assumed the entire chromosome was covered by
reads and used the chromosome lengths from the UCSC genome
browser. If this assumption is not true, then an inflated L will
underestimate h. Diversity values for indels were not calculated
because indel data was not available for Dr. Watson’s genome.
Supporting Information
Figure S1 Protein-affecting predictions for nsSNPs that are
novel or in dbSNP with unknown allele frequencies. When
categorized by zygosity, the percentage of predicted-protein-
affecting nsSNPs is similar between the different categories for
homozygous nsSNPs, but not for the heterozygous nsSNPs.
Found at: doi:10.1371/journal.pgen.1000160.s001 (0.25 MB TIF)
Figure S2 Diversity rates for indels, based on size.
Found at: doi:10.1371/journal.pgen.1000160.s002 (0.12 MB TIF)
Figure S3 An example of an indel that occurs at the N-terminus
of the gene MTCH1. This indel occurs in the first exon, about
30 bp after the translation start site. A start codon just downstream
of the indel may serve as an alternative translation start site. Thus,
the indel may be functionally neutral.
Found at: doi:10.1371/journal.pgen.1000160.s003 (0.17 MB TIF)
Figure S4 Conservation of coding indels with size 3n that are
not located at the N- or C-termini of the protein, near exon
boundaries, or in tandem repeats. The x-axis is the percentile of
amino acid conservation at the indel’s location relative to all of the
positions in the protein. A low percentile indicates that the indel is
located at a nonconserved position in the protein. A high
percentile indicates that the indel is located at a conserved
position, relative to all other positions in the protein.
Found at: doi:10.1371/journal.pgen.1000160.s004 (0.21 MB TIF)
Figure S5 A) The proportion of exons in copy number regions,
tandem repeats, and RepeatMasker regions. The solid bars
represent the percentages observed for exons missing from the
HuRef assembly; the hatched bars represents the percentages
observed for all exons. B) The coverage of exons missing from the
HuRef assembly (solid line) has a bimodal distribution. As a
control, the coverage of exons randomly selected from all exons is
shown (dashed line) and is normally distributed.
Found at: doi:10.1371/journal.pgen.1000160.s005 (0.28 MB TIF)
Figure S6 A) Comparison of the allele frequencies for nsSNPs in
disease genes versus nsSNPs in all genes. The distributions are
similar and not significantly different (p=0.97). B) The percentage
of nsSNPs predicted to affect protein function in disease genes is
similar to nsSNPs in all genes.
Found at: doi:10.1371/journal.pgen.1000160.s006 (0.31 MB TIF)
Figure S7 Genes involved in the melanomapathway [99], overlaid
with HuRef variants. For each gene symbol,a pie chart represents the
HuRef variants found in or within 1 kb of the gene. Variants that
were in coding, UTR, and conserved regions were counted. If a gene
has no pie chart, no variants were found in these regions. The size of
the pie chart corresponds to the number of variants, and colors
correspond to the fraction of variants for each type. Of the 67 variants
found in/near these genes, only 1 was nonsynonymous. The nsSNP
was in TP53, and it is frequent in the CEU population (MAF=0.23).
63% of the variants were in conserved regions.
Found at: doi:10.1371/journal.pgen.1000160.s007 (0.49 MB TIF)
Table S1 Pre-termination codon SNPs.
Found at: doi:10.1371/journal.pgen.1000160.s008 (0.06 MB XLS)
Table S2 Variants validated by targeted resequencing.
Found at: doi:10.1371/journal.pgen.1000160.s009 (0.03 MB XLS)
Table S3 nsSNPs in disease genes.
Found at: doi:10.1371/journal.pgen.1000160.s010 (0.40 MB XLS)
Table S4 Indels in disease genes.
Found at: doi:10.1371/journal.pgen.1000160.s011 (0.03 MB XLS)
Table S5 Diversity rates.
Found at: doi:10.1371/journal.pgen.1000160.s012 (0.04 MB XLS)
Text S1 Supplemental text.
Found at: doi:10.1371/journal.pgen.1000160.s013 (0.03 MB DOC)
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